Catalyst Event

InnoCare Pharma Ltd (9969) · Other

From Akros SCHK HK-Global Genomics Index (ASHGGENM)

4/28/2026, 12:00:00 AM

OtherSentiment: Positive

On 2026-04-28, InnoCare announced the first patient has been dosed in its Phase III registrational clinical trial for Orelabrutinib for the treatment of systemic lupus erythematosus (SLE). This clinical milestone is estimated to have a ~5% price impact as it advances a key pipeline asset.

Korean Translation

2026년 4월 28일, 전신성 홍반성 루푸스(SLE) 치료를 위한 오레라브루티닙(Orelabrutinib)의 3상 등록 임상시험에서 첫 환자 투여를 완료했다고 발표함. 주요 파이프라인의 임상 진전에 따라 약 5%의 주가 영향이 예상됨.

Related Recent Events

View Full Timeline